Istituto Nazionale Dei Tumori

Research site

Italy Via Mariano Semmola, 80131 Naples, Italy

Hormone receptor positive HER2 negative breast cancer · Triple negative breast cancer · Malignant peritoneal neoplasm
Adults and children

About Specializations

Istituto Nazionale Dei Tumori in Naples, Italy specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Triple negative breast cancer, Malignant peritoneal neoplasm, Fallopian tube cancer, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Via Mariano Semmola80131 NaplesItaly

Open in maps ↗

Recruiting now: no trials
Conditions studied: 27

More sites in Naples Italy

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

15 clinical trials

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Azenosertib
Sponsor:K-Group Beta Inc.

Contact Research Centre

Non-small cell lung cancer+1

Not yet recruiting

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Universita' Degli Studi Di Torino

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Inhibrx Biosciences Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Hodgkin's disease

Not recruiting

Study on the Safety and Effects of AZD7789 for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo

Study on the Safety and Effects of AZD7789 for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Diphenhydramine
Sponsor:AstraZeneca AB

Contact Research Centre

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Lisocabtagene Maraleucel
Sponsor:Celgene Corp.

Contact Research Centre

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Cervix carcinoma

Not recruiting

Study on the Effectiveness of HPV 9-Valent Vaccine in Women Undergoing LEEP for High-Grade Cervical Lesions or Early Cervical Cancer

Registered drug

Study on the Effectiveness of HPV 9-Valent Vaccine in Women Undergoing LEEP for High-Grade Cervical Lesions or Early Cervical Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Water For Injection
Sponsor:Azienda Unita Sanitaria Locale Toscana Nord Ovest

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites